Abstract Coronary artery disease (CAD) patients (n=235), comprising minimal (CAD", n=124) and severe (CAD + , n = l l l ) CAD, were recruited on the basis of their angiographic scores. Male control subjects (n=123) were selected randomly from the Caerphilly Heart Study cohort. Subjects were genotyped for the Ser*"-Ter mutation and HindlUJPvu II restriction fragment length polymorphisms of the lipoprotein lipase gene and investigated for associations with severity and development of CAD and lipid and lipoprotein levels. The Ser*"-Ter mutation showed no significant associations with CAD or dyslipidemia but was related to favorable lipid and lipoprotein profiles. The H2H2 genotype (P<.05) and H2 allele (P=.O5) were significantly more frequent in CAD + versus CAD" and control subjects versus CAD". H2H2 sub-
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Abstract Coronary artery disease (CAD) patients (n=235), comprising minimal (CAD", n=124) and severe (CAD + , n = l l l ) CAD, were recruited on the basis of their angiographic scores. Male control subjects (n=123) were selected randomly from the Caerphilly Heart Study cohort. Subjects were genotyped for the Ser*"-Ter mutation and HindlUJPvu II restriction fragment length polymorphisms of the lipoprotein lipase gene and investigated for associations with severity and development of CAD and lipid and lipoprotein levels. The Ser*"-Ter mutation showed no significant associations with CAD or dyslipidemia but was related to favorable lipid and lipoprotein profiles. The H2H2 genotype (P<.05) and H2 allele (P=.O5) were significantly more frequent in CAD + versus CAD" and control subjects versus CAD". H2H2 sub-F amilial clustering of coronary artery disease (CAD) has long been recognized 1 ' 2 and confirmed by many studies, implicating a genetic predisposition. 3 ' 4 In most subjects the genes conferring susceptibility to CAD have yet to be identified, but they have been elucidated in a small number of cases, eg, mutations of the low-density lipoprotein (LDL) receptor gene that determine the onset of premature CAD in familial hypercholesterolemia. 5 Numerous large studies have established the association of lipid and lipoprotein abnormalities with an increased risk for the development of CAD. 69 Between 50% and 80% of myocardial infarction survivors have some form of dyslipoproteinemia, 10 and one of the most common types is hypertriglyceridemia accompanied by low high-density lipoprotein (HDL) levels. it is a rate-limiting enzyme in the clearance of triglyceride-rich lipoproteins from the circulation. 13 ' 14 Other known influences of the enzyme include apolipoprotein (apo) and phospholipid exchange between very-lowdensity lipoprotein (VLDL) and HDL, 15 thereby affecting HDLj conversion to HDL 2 and LDL generation derived from VLDL clearance. 1617 LPL is a glycoprotein synthesized in parenchymal cells (primarily adipose tissue and muscle) from which it is secreted and anchors to the vascular endothelium bound to glycosaminoglycans.
18
- 19 It appears to be active as a noncovalently linked homodimer that loses activity progressively and rapidly on dissociation.
2022 Activation of LPL requires apoC-II 23 at the lipid interface, an obligatory cofactor present in chylomicrons, VLDL, and HDL.
The human LPL gene has been cloned and localized to chromosome 8p22 and spans approximately 30 kb. 2426 The first 9 of its 10 exons code for a protein containing 475 amino acids, including a 27-amino acid signal peptide that is cleaved posttranslationally to yield mature LPL with a molecular weight of approximately 60 000 D.
2527 - 28 Extensive research has been directed at genetic variants in dyslipidemia to elucidate the genes predisposing to CAD. 10 ' 29 Restriction fragment length polymorphisms (RFLPs) have been widely used as markers to determine associations of DNA sequence variations in and around such candidate genes with diseases or biochemical traits. 3032 The RFLPs reported in the LPL gene have shown the following significant associations:
the Hindlll RFLP (intron 8) with primary hypertriglyceridemia, 33 -34 hypercholesterolemia, 35 HDL levels, 35 and premature CAD 34 ; and the Pvu II RFLP (intron 6) with primary hypertriglyceridemia. 33 These findings suggest that a relatively common mutation at the LPL gene locus, in linkage disequilibrium with these RFLPs, may be predisposing to dyslipidemia and also conferring increased risk for the development of CAD.
Recently, the first common mutation within an exon of the LPL gene was discovered just 635 bp downstream from the HindlW RFLP (intron 8), involving a Ser^-Ter mutation. 36 The Ser^'-Ter mutation is a consequence of a C-G transversion at nucleotide 1595 in exon 9, converting the serine 447 codon (TCA) to a premature termination codon (TGA). This would be anticipated to yield a truncated enzyme lacking the two carboxy terminal amino acids (Ser-Gly).
In this study we have investigated the Ser w -Ter mutation to determine whether it influences the development or severity of CAD. In view of its proximity to the RFLPs, we analyzed whether the RFLPs are markers for the Ser^-Ter mutation, thereby accounting for the previously reported RFLP associations. We have also examined for possible effects of the mutation on plasma lipid and lipoprotein levels and in addition any associations with the RFLPs.
Methods

Subjects
White subjects were recruited over 18 months from 1371 consecutive patients undergoing coronary angiography during investigation of chest pain at the Department of Cardiology, University of Wales College of Medicine, Cardiff. The extent of coronary atherosclerosis was defined by the modified Brandt scoring system 37 using a scale of 0 to 15. Patients were selected for the study having scores of less than 4.5 or greater than 8.5, constituting groups with minimal (CAD', n=124) and severe (CAD + , n = l l l ) atherosclerosis, respectively. Only patients with a fasting plasma glucose less than 6.5 mmol/L were recruited. After recruitment of angiographic subjects, a male population-derived control group was collected from the same region of South Wales (n=123); this involved the random selection of subjects from the Caerphilly Prospective Heart Disease Study, details of which are described elsewhere. 38 No angiography was performed on the population control group because of ethical considerations. This precluded us from obtaining the ideal negative control group for comparisons with CAD + subjects, as we are unable to perform angiograms on healthy individuals to determine an asymptomatic, angiographically defined disease-free group. However, a population control subgroup (n=92), comprising asymptomatic and clinically disease-free subjects, was analyzed after exclusion of subjects with a diagnosis of CAD (namely, World Health Organization criteria for myocardial infarction or on angiography). Although the CAD" group does not represent diseasefree or healthy subjects, it provides a "control" group for the CAD + patients to analyze the severity of CAD. No angiographic patients had received any hypolipidemic drugs or dietary advice.
Lipid Measurements
Lipid measurements were undertaken on serum separated within 6 hours of venesection from clotted venous samples collected after a 12-hour fast. Cholesterol 39 and triglyceride 40 levels were measured using fully enzymatic methods (Boehringer Mannheim). HDL cholesterol was measured after phosphotungstate/magnesium precipitation 41 and apoA-I and apoB by immunonepholometry (Beckman Immunochemistry Analyzer). After reduction/hydrolysis of apo(a) from the lipoprotein(a) [Lp(a)] particle, apo(a) was measured using a two-site immunoradiometric assay (Pharmacia Diagnostics AB); 1 U/L is equivalent to 0.07 mg/dL of Lp(a). LDL cholesterol (LDL-C) was calculated using the Friedewald formula.
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Isolation of DNA
DNA was isolated from frozen EDTA whole blood by a sucrose lysis procedure as described elsewhere. 43 It was redissolved in Tris-EDTA buffer (10 mmol/L Tris, 1 mmol/L EDTA, pH 7.6) and stored at -20°C.
Oligonucleotides
Primers for polymerase chain reaction were synthesized by standard £-cyanoethyl phosphoramidite chemistry using a Biotech BT 8500 DNA Synthesizer and purified on a Sephadex G-25 column. The primer sequences were derived from published data 36 and from data supplied by K. Oka ( The mixture was overlaid with mineral oil. All tubes, pipette tips, and buffers were autoclaved, and the reaction mixture was UV irradiated before addition of genomic DNA and Taq DNA polymerase to minimize contamination. 44 Blank controls containing no genomic DNA were run with each set of amplifications. The amplification cycle was performed on a Perkin-Elmer Cetus 480 Thermal Cycler and entailed 5 minutes of denaturation at 96°C followed by 30 cycles of 1 minute at 94°C, 1 minute at 55°C, and 1 minute at 72°C. This was followed by 7 minutes of extension at 72°C.
Digestion and Electrophoresis
Five microliters of digestion mixture containing the manufacturer's recommended restriction buffer and 10 U restriction enzyme were added to the amplification product and incubated at 37°C overnight: Hinfl (New England Biolabs) for the Ser" 7 -Ter mutation, Hindlll (Gibco, BRL) for the intron 8 RFLP, and Pvu II (Gibco, BRL) for the RFLP in intron 6. Subsequently, the samples were electrophoresed in TBE buffer (89 mmol/L Tris-borate, 2 mmol/L EDTA, pH 8.3): the Ser^'-Ter mutation in 10% nondenaturing polyacrylamide gels at 400 V for 90 minutes and Hindlll/Pvu II RFLPs in 2% agarose gels at 100 V for 60 minutes. DNA was visualized by staining the gels with ethidium bromide (0.5 p.g/mL) and transillumination with UV light.
Statistical Analysis
Genotype distributions between the study groups were analyzed by constructing 2x2 and 3x2 contingency tables and performing x 2 analysis. Variation in the biochemical traits with respect to genotypes and unequivocal haplotypes were analyzed by performing analysis of covariance adjusted for age and body mass index. Similar comparisons of genotype and haplotype distribution were undertaken using x 1 analysis after biochemical traits were divided into tertiles. Triglycerides and Lp(a) were log 10 transformed before analysis. Analyses were performed using the MINITAB, SPSS/PC+, and SAS statistical packages. 
Results
Epidemiologic data show that biochemical traits and the natural history of CAD differ between the sexes; therefore, male and female patients were analyzed separately. Furthermore, our population-derived control group consisted entirely of men, and significant differences were apparent in age and body mass index between the sexes in our angiographic patients. Table 1 summarizes the adjusted biochemical characteristics for the study groups for men and women. Clinical details have been described elsewhere. 45 As expected, the mean levels of cholesterol, triglycerides, LDL-C, and Lp(a) were significantly and progressively higher between the men in the control, CAD", and CAD + groups, respectively. HDL levels followed a similar significant inverse trend. The women did not exhibit the same significant trends regarding triglyceride and HDL levels, probably reflecting the smaller numbers of women recruited into the study.
Biochemical Characteristics and CAD
Genotyping
The 
LPL Genotypes in Control and
Angiographic Subjects
The genotype distributions of the Ser^'-Ter mutation and RFLPs examined at the LPL gene locus were in Hardy-Weinberg equilibrium and are shown in Table 2 for the male subjects. Comparison between the CAD + and CAD" groups did not show any significant differences in genotype or allelic distributions in female patients (data not shown). Ser"
7
-Ter Mutation Allelic frequencies in pooled male subjects (data not shown) for the Ser^-Ter mutation were 0.09 (G allele) and 0.91 (C allele). No significant differences in distribution of genotypes or alleles were observed between the CAD + , CAD", and control groups.
Pvu n RFLP Allelic frequencies in the control group were 0.45 (PI) and 0.55 (P2). Comparison of the genotype and allelic frequencies between the control, CAD", and CAD + groups showed no significant differences in distribution.
HindUl RFLP
There was a significantly higher frequency of the H2H2 genotype among subjects with CAD + versus CAD" (P<.05). Examination of allelic frequencies showed a significant association of the H2 allele with the severity of CAD (CAD + versus CAD", />=.O5). Similarly, significant differences were observed between the CAD" patients and control subjects for both genotypic and allelic distributions.
LPL Genotypes and Biochemical Traits
Comparisons of lipid, lipoprotein, and apo levels based on genotypes at the LPL gene locus among the control group are presented in Table 3 .
Sef" 7 -Ter Mutation
Comparisons among the control group of subjects possessing at least one Ser^'-Ter mutation (CG or GG) with those without did not show any significant differences in biochemical traits. However, the homozygotes with the Ser" 7 -Ter mutation (n=3) had significantly higher HDL levels (mean, 1.69 mmol/L) than either the heterozygotes or wild-type homozygotes (mean, 0.87 mmol/L) (P<.002) when all the male data were pooled, but interpretations should remain cautious because of the small number of homozygous GG patients.
Pvu II RFLP
Control subjects with the genotype P2P2 had significantly lower HDL levels than control subjects with alternative genotypes for this RFLP (P<.03). Conversely, these individuals showed a trend toward higher LDL-C levels, which failed to reach similar statistical significance (P<.054).
Hindlll RFLP
Comparisons among the control group showed significantly higher cholesterol (/>=.O21), LDL-C (P=.01), and apoB (P<.005) levels in subjects with the genotype H2H2 compared with H1H2 or H1H1.
Pooled data involving all male subjects are represented in Table 4 and show stronger associations. This probably reflects the larger numbers of individuals being analyzed. The strongest association with the HindVW RFLP was again found with apoB (P=.0OO2). In the pooled group the H2 allele was also associated with significantly higher triglyceride levels (P<.04).
Haplotype Associations
Unequivocal haplotypes were constructed using data from all subjects having heterozygosity at no more than one site out of the three studied. The Ser w -Ter mutation was never observed on the same chromosome as the alleles of the RFLPs containing the restriction sites P2 (Pvu II) and H2 (Hin&WX). The pooled haplotype distributions for the male subjects showed no significant differences between the CAD + , CAD", and control groups. However, a significant association of haplotypes was observed with biochemical traits on comparisons within these groups (data not shown).
P,HjC Haplotype
On comparisons among control subjects, this haplotype was associated with significantly lower cholesterol BMI indicates body mass Index; HDL, high-density llpoprotein; Apo, apdipoprotein; LDL-C, low-density lipoprotein cholesterol; and Lp(a), lipoprotein(a).
• levels (F<.006) and LDL-C levels (P<.002). There was also a trend toward lower apoB levels in subjects with this haplotype among the control group (P=.O63).
P 2 H 2 C Haplotype
Comparison among the control group showed that subjects with this haplotype had significantly lower HDL levels (P=.O5).
P 2 H,C Haplotype
Comparison among subjects with CAD + revealed significantly lower cholesterol levels (P<.007) and apoB levels (/ ) <.013) with this haplotype.
P,H,G Haplotype
Comparisons among subjects with CAD" showed significantly higher HDL levels with this haplotype (P=.0001). These individuals also showed a trend toward lower triglyceride levels (Z'=.O84).
Discussion
The Ser^'-Ter mutation is the first report of a common, coding sequence mutation at the LPL gene locus. The functional significance of the carboxy terminal region of LPL remains uncertain. It has been postulated to function in the interaction of LPL with lipid substrates. 4748 In vitro LPL activity studies suggest that the Ser^'-Ter mutation appears to influence hydrolysis of substrates dependent on their nature. 4850 Although LPL-deficient states give rise to type I hyperlipidemia, this is not usually associated with a predisposition to CAD. However, the obligate heterozygote state has recently been implicated in familial combined hyperlipidemia, 31 in which there is a predisposition to premature and severe CAD. 52 Our data suggest that the Ser^-Ter mutation conveys no risk for the development or severity of CAD and has little influence on dyslipoproteinemia.
The 34 Interestingly, we observed significant associations of the H2H2 genotype and the H2 allele with the severity of CAD (CAD + versus CAD") but no differences between the angiographic groups (alone or pooled) versus random population-derived control subjects. This may partly reflect the heterogeneous nature of the control group, which was composed of approximately 23% of subjects known to have CAD and a further 11% having possible CAD, based on clinical histories. This may have affected the power of our study to detect any asymmetric genotype distribution between the CAD and control groups. However, comparison of the control subgroup (which excludes subjects with known CAD) with CAD" showed a significant difference in genotype and allelic distribution for the HindUl RFLP. This was observed despite the presence of subjects with possible CAD within this subgroup. We are unable to explain the absence of a similar genetic difference on comparison with CAD + . Our observations among the control and pooled subjects support previous associations of the H2H2 genotype with significantly elevated total cholesterol, LDL-C, and triglyceride levels. In addition, we find that the strongest associations are with apoB levels. This association reflects a significant increase in levels of apoB-containing lipoproteins in subjects with the H2H2 genotype. LPL has a pivotal role in lipoprotein metabolism, affecting VLDL and chylomicron clearance from the circulation, thereby influencing the generation of other apoB-containing lipoproteins in a subject's "lipoprotein pool." Assuming that subjects possessing the H2H2 genotype maintain an unchanged lipid content per apoB-containing lipoprotein, compared with alternative genotypes, in their "pool," we would anticipate an association between the lipids and this genotype equivalent to that found with apoB. However, the lipid associations were not of the same order; thus, increased numbers of morphologically unchanged lipoproteins cannot solely account for the associations observed in these subjects. This disparity between the associations of LDL-C and lipids compared with apoB implicates genetic determinants of LPL influencing its effects on the "lipoprotein pool," which may extend beyond the determination of the numbers of apoB-containing lipoproteins. This would be consistent with the morphological observations reported in subjects with hypertriglyceridemia 54 - 55 and changes observed in HDL, VLDL, and chylomicron turnover with variations in LPL activity.
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The Ser^'-Ter mutation exhibited few associations with biochemical traits. A nonsignificant trend was observed between higher HDL levels and the Ser** 7 -Ter mutation similar to that reported by Stocks et al. 46 Moreover, the HDL levels among the control group were significantly lower with the genotype P2P2, yet we found no significant associations between HDL levels and the HindUl RFLP. During the preparation of this manuscript Peacock et al 53 published their study of the LPL gene locus in a Swedish population with previous myocardial infarction showing a nonsignificant trend between HDL levels and the Pvu II RFLP, consistent with our findings. In contrast, Heinzmann et al 35 reported an association between the H2H2 genotype and significantly higher HDL levels, inconsistent with previous reports, 33 -53 our data, and the linkage disequilibrium observed between the PI and HI alleles. This disparity probably reflects differences in subject selection between our study and that of Heinzmann et al; the latter involved analyses of biochemical and genetic traits using pooled male/female data, and their subject recruitment was not founded on a CAD phenotype and did not include random population-derived control subjects. The inverse correlation between HDL levels, particularly HDL 2 , and the extent of CAD has long been recognized.
-
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- 59 Turnover studies suggest that the best predictor of HDL levels may be the HDL apo fractional catabolic rate, 60 -61 while HDL particle size shows a strong inverse correlation with both fractional catabolic rate and triglyceride levels. Our data suggest that, in addition to the genes that influence HDL apo fractional catabolic rate, the LPL gene may also influence HDL levels. How the LPL gene has such an influence is unclear, but it may be an indirect consequence of altered processing of lipoproteins by LPL, thereby affecting HDL 2 generation rates.
Our data suggest that a putative mutation at or near the LPL gene locus, marked by the H2 allele, predisposes to dyslipidemia and, possibly, the severity of CAD; the Ser^-Ter mutation is clearly not this mutation. The underlying mechanism may involve an etiologic mutation at or near the LPL gene affecting clearance of apoBcontaining lipoproteins, possibly associated with morphological changes in these particles. This would account for the associations observed between the H2H2 genotype and the H2 allele with dyslipidemia and CAD. Clearly, further work is required to investigate the morphology of lipoproteins with Mndlll genotypes and to continue the search for an underlying etiologic mutation.
